Skip to main content
. 2021 Dec 15;126(6):865–873. doi: 10.1038/s41416-021-01619-z

Table 2.

Molecular characteristics of PCCRCs versus DCRCs.

Features PCCRCs (n = 122) DCRCs (n = 98) P value* FDR**
APC gene mutation 37/93 (39.8) 39/79 (49.4) 0.268
BRAF gene mutation 17/93 (18.3) 8/79 (10.1) 0.195
FBXW7 gene mutation 8/93 (8.6) 9/79 (11.4) 0.723
KIT gene mutation 19/93 (20.4) 18/79 (22.8) 0.851
KRAS gene mutation 32/93 (34.4) 24/79 (30.4) 0.690
PIK3CA gene mutation 16/93 (17.2) 13/79 (16.5) 1.000
PTEN gene mutation 11/93 (11.8) 6/79 (7.6) 0.502
SMAD4 gene mutation 8/93 (8.6) 9/79 (11.4) 0.723
TP53 gene mutation 36/93 (38.7) 38/79 (48.1) 0.278
Gain of chromosome 13q 52/105 (49.5) 60/88 (68.2) 0.303
Loss of chromosome 17p 45/105 (42.9) 42/88 (47.7) 0.986
Loss of chromosome 18q 49/105 (46.7) 64/88 (72.7) 0.107
MSI 26/120 (21.7) 9/94 (9.6) 0.029
CIMP high profile 61/122 (50.0) 32/98 (32.7) 0.014

PCCRC post-colonoscopy colorectal cancer, DCRC detected colorectal cancer, FDR false detection rate, MSI microsatellite instability, CIMP CpG island methylator phenotype.

*P value < 0.05 considered significant; **FDR < 0.2 considered significant.